Hostname: page-component-848d4c4894-xm8r8 Total loading time: 0 Render date: 2024-06-27T10:10:47.706Z Has data issue: false hasContentIssue false
  • English
  • Français

Lipoatrophy in Patients with Multiple Sclerosis on Glatiramer Acetate

Published online by Cambridge University Press:  02 December 2014

Catherine M. Edgar ,
Donald G. Brunet ,
Paul Fenton ,
E. Vee McBride  and
Peter Green
Catherine M. Edgar
Affiliation:
MS Clinic, Kingston General Hospital and Department of Medicine, Queen’s University, Kingston, Ontario, Canada
Donald G. Brunet
Affiliation:
MS Clinic, Kingston General Hospital and Department of Medicine, Queen’s University, Kingston, Ontario, Canada
Paul Fenton
Affiliation:
Department of Radiology, Kingston General Hospital and Queen’s University, Kingston, Ontario, Canada
E. Vee McBride
Affiliation:
MS Clinic, Kingston General Hospital and Department of Medicine, Queen’s University, Kingston, Ontario, Canada
Peter Green
Affiliation:
Department of Dermatology, University of Ottawa, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Patients with relapsing remitting multiple sclerosis on the disease modifying therapy of glatiramer acetate may be experiencing an adverse reaction of lipoatrophy at the sites of their subcutaneous injections. The purpose of this study was to complete a full examination of the injection site areas for users of glatiramer acetate, and to examine the relationship between lipoatrophy and patient characteristics.

Methods:

Glatiramer acetate users were identified by means of chart review. Over six months, during regular clinic appointments, assessment included a full examination of injection site areas including visual inspection and manual palpation. Additional patient and clinical characteristics were obtained by means of chart review and patient questioning.

Results:

Seventy-six patients had been or were current users of glatiramer acetate. Of these, 34 (45%) had evidence of lipoatrophy in at least one injection site area. All were female, and five had severe, nine had moderate and 20 had mild lipoatrophy. In some cases, lipoatrophy occurred within months of therapy initiation. Case reviews are included for five of the 34 patients, along with photographs of the lipoatrophy, a magnetic resonance image and comments on skin biopsies.

Conclusion:

Prevalence of lipoatrophy was much higher than expected. Possible reasons for this adverse reaction are explored and suggested treatment recommendations are reviewed. Lipoatrophy can be very disfiguring and is thought to be permanent, and the psychological impact can be significant. It is, therefore, important that patients be aware of the possibility of lipoatrophy, be able to identify it and discontinue injecting in areas where it is identified.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 31 , Issue 1 , February 2004 , pp. 58 - 63
Copyright
Copyright © The Canadian Journal of Neurological 2004

References

1.Johnson, KP, Brooks, BR, Cohen, JA, et al.Copolymer 1 reducesrelapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology 1995;43:1268–1276CrossRefGoogle Scholar
2.Drago, F, Rongioletti, F, Battifoglio, ML, Rebora, A.Localizedlipoatrophy after acupuncture [letter]. Lancet 1996;347:1484.CrossRefGoogle ScholarPubMed
3.Drago, F, Brusati, C, et al.Localized lipoatrophy after glatirameracetate injection in patients with remitting-relapsing multiple sclerosis. Arch Dermatol 1999;138:1277–1278.CrossRefGoogle Scholar
4.McBride, EV, Brunet, DG, Edgar, CM.Nonadherence toimmunmodulation in multiple sclerosis. Int J MS Care 2002;4:85.Google Scholar
5.Mancardi, GL.Localized lipoatrophy after prolonged treatment withcopolymer-1. J Neurol 2000;247:220–221.CrossRefGoogle Scholar
6.Hwang, L, Orengo, I.Lipoatrophy associated with glatiramer acetateinjections for the treatment of multiple sclerosis. Cutis 2001;68:287–288.Google Scholar
7.Wolinsky, JS.Copolymer-1 a most reasonable alternate therapy forearly relapsing-remitting MS with mild disability. Neurology 1995;45:1245–1247.Google Scholar
8.Brunet, DG, Hopman, WM, Singer, MA, Edgar, CM, MacKenzie, TA.Measurement of health-related quality of life in multiple sclerosis patients. Can J Neurol Sci 1996;23:99–103.Google Scholar
9.Hopman, WM, Coo, H, Brunet, DG, Edgar, CM, Singer, MA.Longitudinal assessment of health-related quality of life (HRQL) of patients with multiple sclerosis. Int J MS Care 2000;2:15–20,26.Google Scholar
10.Ware, JE.SF-36 Health Survey Manual and Interpretation Guide.Boston, Massachusetts: The Health Institute, New EnglandMedical Centre, 1993.Google Scholar